| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/15/2014 | CA2383877C Method for detecting the expression of an envelope protein of a human endogenous retrovirus and uses of a gene coding for said protein |
| 04/15/2014 | CA2328414C Methods for detecting and inhibiting angiogenesis |
| 04/12/2014 | CA2829650A1 Compositions and methods of forming films for improved drug delivery |
| 04/10/2014 | WO2014055999A2 Treatment of ocular disorders |
| 04/10/2014 | WO2014055996A2 Rho kinase inhibitors |
| 04/10/2014 | WO2014055977A2 Modulation of branched amino acid concentrations to treat metabolic diseases |
| 04/10/2014 | WO2014055954A1 Progesterone containing oral dosage forms and kits |
| 04/10/2014 | WO2014055944A1 Small molecules as anti-hiv agents that disrupt vif self-association and methods of use thereof |
| 04/10/2014 | WO2014055941A2 Compounds and methods for targeted immune system delivery |
| 04/10/2014 | WO2014055938A1 Novel compounds, their preparation and their uses |
| 04/10/2014 | WO2014055934A2 Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
| 04/10/2014 | WO2014055932A1 Integrated neuromodulation system for mood enhancement of a living human subject |
| 04/10/2014 | WO2014055928A2 Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
| 04/10/2014 | WO2014055921A1 1, 2, 4-oxadiazoles azetidine derivatives as sphingosine-1 phosphate receptors modulators |
| 04/10/2014 | WO2014055916A1 Substituted aryl-1,2,4-oxadiazole derivatives useful for the treatment of interalia ocular or inflammatory diseases |
| 04/10/2014 | WO2014055913A1 Treatment of cancer |
| 04/10/2014 | WO2014055911A1 Bicyclic 1, 2, 4-oxadiazoles derivatives as sphingosine-1 phosphate receptors modulators |
| 04/10/2014 | WO2014055905A1 Methods for enhancing the effect of egcg on mitigating skeletal muscle loss |
| 04/10/2014 | WO2014055801A1 Phosphodiesterase inhibitors for treating taste and smell disorders |
| 04/10/2014 | WO2014055768A1 Inhibitors of protein tyrosine phosphatases |
| 04/10/2014 | WO2014055672A1 Clay product and uses thereof |
| 04/10/2014 | WO2014055667A1 Enalapril compositions |
| 04/10/2014 | WO2014055647A1 (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases |
| 04/10/2014 | WO2014055629A1 Multifunctional radical quenchers for the treatment of mitochondrial dysfunction |
| 04/10/2014 | WO2014055627A1 Water-based personal lubricants with a silicone component |
| 04/10/2014 | WO2014055624A1 Methods relating to dna-sensing pathway related conditions |
| 04/10/2014 | WO2014055618A1 Solid state forms of hiv inhibitor: hemi-succinate of (2s)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid) |
| 04/10/2014 | WO2014055595A1 Indoline compounds as aldosterone synthase inhibitiors related applications |
| 04/10/2014 | WO2014055591A1 Angiotensin in treating brain conditions |
| 04/10/2014 | WO2014055588A1 Treatment of mild and moderate alzheimer's disease |
| 04/10/2014 | WO2014055548A1 Anti-fibrotic pyridinones |
| 04/10/2014 | WO2014055493A1 Methods and systems for polymer precipitation and generation of particles |
| 04/10/2014 | WO2014055474A1 Mannose derivatives for treating bacterial infections |
| 04/10/2014 | WO2014055426A1 Non-aqueous taxane nanodispersion formulations and methods of using the same |
| 04/10/2014 | WO2014055415A1 Cancer treatments |
| 04/10/2014 | WO2014055311A1 Substituted isoquinolines as crth2 receptor modulators |
| 04/10/2014 | WO2014055297A1 Novel urea compounds |
| 04/10/2014 | WO2014055142A1 Inhibitors of hepatitis c virus polymerase |
| 04/10/2014 | WO2014055069A1 Solid forms comprising an inhibitor of hcv ns5a, compositions thereof, and uses therewith |
| 04/10/2014 | WO2014055055A1 Pharmaceutical composition of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof for the treatment of cerebrovascular disease and neurodegenerative diseases of the central nervous system |
| 04/10/2014 | WO2014055054A1 Use of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof in pharmaceutical compositions as a neuroretinal protector |
| 04/10/2014 | WO2014055053A1 Pharmaceutical composition of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof for the treatment of cardiovascular disease |
| 04/10/2014 | WO2014055047A1 Combination of idebenone and donezepil |
| 04/10/2014 | WO2014054980A1 Na-acyl derivatives of aminoacyl-2-cyanopyrrolidine-inhibitors of prolyl endopeptidase and dipeptidyl peptidase-iv, having hypoglycemic, antihypoxic, neuroprotective action and action of cognitive function improvement |
| 04/10/2014 | WO2014054970A1 Solid dosage form having an anorectic effect (variants) |
| 04/10/2014 | WO2014054965A1 Combination for the prophylaxis and treatment of behavioural, mental and cognitive disorders |
| 04/10/2014 | WO2014054927A1 Amphiregulin-specific double-helical oligo-rna, double-helical oligo-rna structure comprising double-helical oligo-rna, and composition for preventing or treating respiratory diseases containing same |
| 04/10/2014 | WO2014054880A1 Novel laxative composition with improved stability, containing polyethylene glycol and vitamin c |
| 04/10/2014 | WO2014054841A1 Composition comprising material for controlling expression of abh antigen |
| 04/10/2014 | WO2014054798A1 Drug for inhibiting malignant tumor metastasis |
| 04/10/2014 | WO2014054651A1 Sleep-improving agent, non-rem sleep time-increasing agent, and sedative agent |
| 04/10/2014 | WO2014054635A1 Imidazole derivative |
| 04/10/2014 | WO2014054634A1 Pyrimidine derivative |
| 04/10/2014 | WO2014054588A1 Nanogel/exosome complex and dds |
| 04/10/2014 | WO2014054421A1 Peyer's patch activator |
| 04/10/2014 | WO2014054058A2 Novel compounds, their synthesis and their uses |
| 04/10/2014 | WO2014054026A1 Liposomal drug delivery system |
| 04/10/2014 | WO2014054005A2 Nanosomal preparation of the complex formed by quercetin (or another flavonol, flavone or a derivative thereof) and 2-hydroxypropyl-β-cyclodextrin for intravenous use in cerebral pathological conditions |
| 04/10/2014 | WO2014053974A1 Pharmaceutical compositions of sirolimus |
| 04/10/2014 | WO2014053968A1 Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors |
| 04/10/2014 | WO2014053967A1 Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors |
| 04/10/2014 | WO2014053965A1 Tropomyosin-related kinase inhibitors |
| 04/10/2014 | WO2014053857A1 Protected succinates for enhancing mitochondrial atp-production |
| 04/10/2014 | WO2014053851A1 Treatment of cancer |
| 04/10/2014 | WO2014053694A1 N-prop-2-ynyl carboxamide derivatives and their use as trpa1 antagonists |
| 04/10/2014 | WO2014053691A1 Bis-pyridinium cyclophane derivatives as anti-protozoa drugs |
| 04/10/2014 | WO2014053666A1 Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| 04/10/2014 | WO2014053665A1 Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| 04/10/2014 | WO2014053650A1 Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors |
| 04/10/2014 | WO2014053642A1 Use of glycerophosphoinositols for the treatment of septic shock |
| 04/10/2014 | WO2014053640A1 A NEUTRALIZING RNA APTAMER AGAINST PDGFRβ AND THE USE THEREOF IN THE THERAPY AND DIAGNOSIS OF HYPERPROLIFERATIVE DISEASES |
| 04/10/2014 | WO2014053595A1 Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases |
| 04/10/2014 | WO2014053592A1 Esters of short chains fatty acids for use in the treatment of immunogenic disorders |
| 04/10/2014 | WO2014053581A1 Therapeutically active oxazoline derivatives |
| 04/10/2014 | WO2014053580A1 Anticonvulsant activity of gsk-3beta inhibitors |
| 04/10/2014 | WO2014053579A1 A combination of adrenalin with an antidepressant for use in the treatment of shocks |
| 04/10/2014 | WO2014053568A1 Indolyldihydroimidazopyrimidinone derivatives, preparation thereof and therapeutic use thereof |
| 04/10/2014 | WO2014053533A1 Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation |
| 04/10/2014 | WO2014053516A1 1,2,4-triazine derivatives for the treatment of viral infections. |
| 04/10/2014 | WO2014053491A1 Inhibitors of histone demethylases |
| 04/10/2014 | WO2014053489A1 Compounds for treating the remyelination blockade in diseases associated with the expression of herv-w envelope protein |
| 04/10/2014 | WO2014053482A1 Methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza with invariant nkt cell agonists |
| 04/10/2014 | WO2014053409A1 Benzimidazol.es as cns active agents |
| 04/10/2014 | WO2014053370A1 Edible foam comprising a drug |
| 04/10/2014 | WO2014053328A2 Pharmaceutical compositions |
| 04/10/2014 | WO2014053315A1 Tetrahydroquinoline derivatives and their use as epac inhibitors |
| 04/10/2014 | WO2014053263A1 Pharmaceutical composition for the treatment of hoarseness or sore throat |
| 04/10/2014 | WO2014053262A1 Composition, in particular a pharmaceutical composition, in particular for administration in hoarseness |
| 04/10/2014 | WO2014053210A1 Pyrrolidines |
| 04/10/2014 | WO2014053208A1 7-azaindol-2,7-naphthyridine derivative for the treatment of tumors |
| 04/10/2014 | WO2014053014A1 Modulation of rna activity and vascular permeability |
| 04/10/2014 | WO2014031792A3 Methods of treating epilepsy or status epilepticus |
| 04/10/2014 | WO2014027982A3 Novel effervescent sachet formulations of dapoxetine and a pde5 inhibitor |
| 04/10/2014 | WO2014027777A3 Novel ursolic acid derivative and method for preparing same |
| 04/10/2014 | WO2014027334A3 Oral pharmaceutical composition in the form of microspheres and preparation method |
| 04/10/2014 | WO2014023390A3 (aza-)isoquinolinone derivatives |
| 04/10/2014 | WO2014022340A3 Therapeutic compostions and methods |
| 04/10/2014 | WO2014018926A8 Methods and compositions for determining resistance to androgen receptor therapy |
| 04/10/2014 | WO2014015067A3 Scirpusin a and scirpusin band anti-obesity potential thereof |
| 04/10/2014 | WO2014007972A3 Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinphrine |